Three-dimensional (3D) Rectal Water Contrast Transvaginal Ultrasonography Versus Computed Colonography in the Diagnosis of Rectosigmoid Endometriosis

Sponsor
Ospedale Policlinico San Martino (Other)
Overall Status
Completed
CT.gov ID
NCT04295343
Collaborator
(none)
68
1
35.1
1.9

Study Details

Study Description

Brief Summary

Rectosigmoid involvement by endometriosis causes intestinal symptoms such as constipation, diarrhea, and dyschezia. A non-invasive diagnosis of bowel endometriosis is relevant to provide the patients information on the potential hormonal or surgical treatments. The objective of the current study was to compare the performance of three-dimensional rectal water contrast transvaginal ultrasonography (3D-RWC-TVS) and computed colonography (CTC) in predicting the presence and characteristics of rectosigmoid endometriosis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Three-dimensional (3D) rectal water contrast transvaginal ultrasonography
  • Diagnostic Test: Computed colonography

Study Design

Study Type:
Observational
Actual Enrollment :
68 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Three-dimensional Rectal Water Contrast Transvaginal Ultrasonography Versus Computed Colonography in the Diagnosis of Rectosigmoid Endometriosis
Actual Study Start Date :
Mar 1, 2017
Actual Primary Completion Date :
Sep 1, 2019
Actual Study Completion Date :
Feb 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Patients with suspicious of rectosigmoid endometriosis

Diagnostic Test: Three-dimensional (3D) rectal water contrast transvaginal ultrasonography
Rectal water contrast transvaginal ultrasonography is based on the distention of rectosigmoid with saline solution. Three-dimensional reconstructions convert standard 2D grayscale ultrasound acquisitions into a volumetric dataset.

Diagnostic Test: Computed colonography
Computed colonography or virtual colonoscopy uses special x-ray equipment to examine the large intestine. During the exam, a small tube is inserted a short distance into the rectum to allow for inflation with gas while computed tomographic images of the colon and the rectum are taken.

Outcome Measures

Primary Outcome Measures

  1. To compare the accuracy of 3D-RWC-TVS and CTC in the diagnosis of rectosigmoid endometriosis. [At maximum 6 months before laparoscopic surgical approach]

    The results of imaging will be compared with surgical and histological findings.

Secondary Outcome Measures

  1. To compare the precision of 3D-RWC-TVS and CTC in estimating the length (mid-sagittal diameter) of the rectosigmoid endometriotic nodules [At maximum 6 months before laparoscopic surgical approach]

    The results of imaging will be compared with surgical and histological findings.

  2. To compare the accuracy of 3D-RWC-TVS and CTC in the diagnosis of multifocal rectosigmoid endometriosis. [At maximum 6 months before laparoscopic surgical approach]

    The results of imaging will be compared with surgical and histological findings.

  3. To compare the precision of 3D-RWC-TVS and CTC in estimating and the distance between the lower margin of the rectosigmoid endometriotic nodules and the anal verge [At maximum 6 months before laparoscopic surgical approach]

    The results of imaging will be compared with surgical and histological findings.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • pain and intestinal symptoms suggestive of rectosigmoid endometriosis
Exclusion Criteria:
  • previous surgical diagnosis of intestinal endometriosis

  • previous radiological diagnosis of intestinal endometriosis (based on Magnetic Resonance or double-contrast barium enema

  • history of colorectal surgery (except appendectomy)

  • contraindications to bowel preparation or computed colonography (such as non-- compliant patients and rectal malformations)

  • previous bilateral ovariectomy

  • psychiatric disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Policlinico San Martino Genova Italy

Sponsors and Collaborators

  • Ospedale Policlinico San Martino

Investigators

  • Study Director: Simone Ferrero, MD, PhD, IRCCS Ospedale Policlinico San Martino

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fabio Barra, Principal Investigator, Ospedale Policlinico San Martino
ClinicalTrials.gov Identifier:
NCT04295343
Other Study ID Numbers:
  • 3dETV-CTC-ENDO
First Posted:
Mar 4, 2020
Last Update Posted:
Jun 1, 2020
Last Verified:
May 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Fabio Barra, Principal Investigator, Ospedale Policlinico San Martino
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2020